Daré Bioscience | Leaders in Vaginal Health and Clinical Development in Women's Health
Dare to be Bold
- Website
- darebioscience.com · all feeds from this site
- Feed URL
https://darebioscience.com/feed/
Read it in your FeedListing reader
Or add to: Feedly Inoreader Raw feed
Latest posts
-
The Missed Generation: If you were born before 1980, this one is for you.
A generation of women missed the early HPV vaccine window. On her Substack, Sabrina Martucci Johnson explores what that means for women in midlife and why knowing your HPV status matters.
-
Press Release: Daré Bioscience Addresses New National Focus on Women’s Health in Virtual Investor “What This Means” Discussion
Sabrina Martucci Johnson, President and CEO, shares her perspective on the recent White House Executive Order and how Daré Bioscience’s growing commercial portfolio and clinical pipeline position the Company to address critical unmet needs in women’s health.
-
Press Release: Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program. VP of Product Development Liz Proos presents Friday, October 30, at 2:30 p.m. ET in Boston.
-
Five Questions to Ask Before Starting Any Hormone Therapy
What should women ask before starting hormone therapy? On her Substack, Sabrina Martucci Johnson shares five questions to help women make informed, evidence-based decisions about their care.
-
Press Release: Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
Premier sponsorship of the HERmedicine and OncoMenopause Consortium® program underscores Daré Bioscience's commitment to addressing unmet women’s health needs, including for women affected by breast cancer. The program addresses non-hormonal approaches to women’s sexual health…
-
Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities
New video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience’s growing commercial portfolio, clinical pipeline and strategic priorities.
-
Press Release: Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting
Medical Director Annie Thurman, MD, FACOG to present adverse event and relative bioavailability data comparing topical Sildenafil Cream with oral sildenafil in healthy male adults.
-
Why We Studied Our Cream in Men
On her Substack, Sabrina Martucci Johnson explains why Daré studied its investigational Sildenafil Cream in men—and what the research can teach us about the formulation for women.
-
Press Release: Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection. DARE-HPV Phase 2 study underway with topline results expected in 2027; program supported by approximately $10 million in…
-
The Operating Discipline Behind Women’s Health Innovation
On her Substack, Sabrina Martucci Johnson shares how scientific rigor shapes Daré—from research and data to the claims a company can stand behind.